Characterization of Optimized Functional-Complementary Dual Insulinotorpic Peptide rolGG

Author(s): Yaofang Zhang , Li Du , Yanling Xu , Lin Tian , Peipei Tu* , Minggang Li* .

Journal Name: Current Pharmaceutical Biotechnology

Volume 18 , Issue 10 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) play a similar but complementary role in the regulation of glucose levels in islet β-cells. This study was aimed to develop a fusion peptide, which combines 4 tandem repeated GLP-1 and 4 tandem repeated GIP (4rolGG), and to investigate its therapeutic effect on type 2 diabetes using a diabetic mice model.

Methods: A 4rolGG expression plasmid was constructed and expressed in BL21 (DE3). By inducting with IPTG, 4rolGG was expressed at a high level, which was confirmed by SDS-PAGE electrophoresis and Western Blotting. Subsequently, 4rolGG was purified by Ni-NTA affinity chromatography and the purity of 4rolGG was up to 90%.

Result and Conclusion: After oral administration of 4rolGG for 4 weeks, streptozotocin-induced diabetic mice showed a dramatic reduction in the levels of plasma glucose, GHbA1C, TC and TG, while the insulin levels were increased significantly.

Keywords: GLP-1, GIP, diabetes, expression, purification, primers.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 10
Year: 2017
Page: [840 - 848]
Pages: 9
DOI: 10.2174/1389201019666171204111908
Price: $58

Article Metrics

PDF: 14
HTML: 4
EPUB: 1
PRC: 1